Du gène au traitement
Project coordinated by Jessica Zucman-Rossi
Over the last 30 years and since the discovery of the first tumor suppressor gene, genetic alterations have been considered to be the main features and also the main causes of human carcinogenesis. An additional level of complexity was identified with the epigenetic control of tumor suppressor genes and oncogenes that may drive carcinogenesis. Sequencing of the entire human genome has provided the basis for comprehensive mapping of cancer genome alterations. Recently, technical progress in cancer research, particularly integral cancer genome sequencing of tumor samples, has extended our knowledge about the genetic events involved in carcinogenesis. Moreover, from a clinical point of view, the use of targeted therapy in human cancers over the last 10 years has highlighted the considerable importance of understanding genetic and epigenetic alterations in order to adapt treatment to these diseases of the genome. The genetic and genomic knowledge of tumors must therefore be translated into clinical practice to improve the accuracy of diagnosis and prognosis.
- Task 1: Integrative microarray technologies
- Task 2: Deep sequencing of tumor genomes
- Task 3: Specific pathways deregulated in tumors will be modelized in cellular or animal models
- Task 4: Validation of markers in clinical practice to improve prognosis prediction and therapeutic response